A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic HER2-negative Breast Cancer

Condition:   Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Interventions:   Drug: BL-B01D1;   Drug: SI-B003 Sponsor:   Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials